Pharmaceuticals
Reconciliation for Indian formulators, API manufacturers, and biosimilar producers
Reconciliation in Pharmaceuticals
Indian pharmaceutical manufacturers sit at the intersection of a five-way statutory collision unlike any other manufacturing sector — the Rule 89(5) inverted-duty structure refund workflow under Notification 14/2022, the DPCO 2013 NPPA ceiling-price recovery and Paragraph 8 monthly-return discipline, the USFDA Form 483 observation remediation with Section 37 versus Ind AS 16 capex-vs-revex classification, the Section 35(2AB) DSIR-recognised weighted deduction on in-house R&D, and the Rs 15,000 crore PLI Pharma multi-year incremental-sales verification against a FY 2019-20 base year. The 22-September-2025 GST 2.0 pivot from the 56th Council meeting moved all drugs to 5 percent, cut medical devices from 18 percent to 5 percent, and moved the notified life-saving formulations to nil-rated — deepening the inversion for API manufacturers and introducing Rule 42/43 apportionment exposure for the nil-rated portion, against the Council FAQ Q10 / Q25 / Q51 pledge of expedited Section 54(3) refunds. A single formulator running an API plant, a formulation plant, a loan-licensing arrangement with a third-party contract manufacturer, and a USFDA-approved export line effectively runs four parallel reconciliation stacks — each with its own statutory anchor and its own timing — that no generic ERP or accounting close can reconcile as a single monthly cycle.
Where reconciliation breaks down
These are the structural problems that generic tools cannot solve for Pharmaceuticals businesses.
22-September-2025 GST 2.0 pivot deepens the pharma inversion
The 56th GST Council on 3-September-2025, effective from 22-September-2025, moved all drugs and formulations to the 5 percent slab, cut medical devices from 18 percent to 5 percent, and moved the notified list of life-saving drug formulations to the nil-rated category. Council FAQ Q10, Q25, and Q51 pledged expedited Section 54(3) inverted-duty refunds against the deeper inversion, but the operational burden falls on the manufacturer: Chapter 30 output at 5 percent (or nil) sits below packaging-input (Chapter 39/48 at 18 percent), solvent-input (Chapter 27 at 18 percent), API-input (Chapter 29/28 at 5-18 percent), and utility-input at various rates. For the nil-rated life-saving portion, Rule 42/43 apportionment applies — ITC on common inputs and capital goods must be split between taxable and exempt supplies, with monthly reversals via GSTR-3B Table 4(B) and the annual reconciliation via Table 5H of GSTR-9. Misclassification cascades into the RFD-01 refund file and into every departmental audit.
Notification 09/2022 permanent block on Chapter 27 solvent ITC
Notification 09/2022-Central Tax (Rate) dated 13-July-2022, effective from 18-July-2022, added Chapter 27 goods (mineral fuels, mineral oils, and products of their distillation — the hexane, isopropanol, methanol, toluene, and ethyl acetate that API manufacturers consume by the tanker) to the permanent-block list for Rule 89(5) inverted-duty refund. The solvent-input ITC accumulates month after month without Section 54(3) recovery, converting from a working-capital delay into a permanent tax cost on the API line. Every API manufacturer must maintain a per-invoice HSN segregation of Chapter 27 solvent input tax versus refundable API and packaging input tax, prove the classification at every departmental audit, and stop the blocked ITC from leaking into the RFD-01 draft — a refund claim that mixes Chapter 27 with recoverable heads is rejected in full.
Loan-licensing Section 143 CGST + Rule 45 challan + ITC-04 + MSME 43B(h)
Indian pharma is dominated by the loan-licensing model — brand-owners despatch APIs, intermediates, and sometimes packaging to third-party contract manufacturers who convert on job-work terms, and the finished formulation is either returned or supplied directly from the job-worker premises. Section 143 of the CGST Act deems the original despatch to be a supply if the goods are not received back within 1 year (inputs) or 3 years (capital goods, moulds, dies, jigs, fixtures), triggering GST with interest from the despatch date. Rule 45 mandates challan-level despatch and receipt tracking, and ITC-04 must be filed quarterly (turnover above Rs 5 crore) or half-yearly, declaring challan-wise input despatch, waste, and finished-goods receipt. Section 43B(h) of the Income Tax Act read with the MSMED Act 2006 disallows the entire expense in the year of accrual if payment to a Udyam-registered micro or small enterprise loan-licensor is not made within 45 days — turning a common brand-owner payment delay into a taxable addition, with MSMED interest accruing at 3x bank rate.
PLI Pharma Rs 15,000 crore multi-year incremental-sales verification
The Production Linked Incentive scheme for Pharmaceuticals notified by the Department of Pharmaceuticals in March 2021 sanctions Rs 15,000 crore across a six-year window, split across Category 1 (biopharmaceuticals, complex generics, patented and off-patent drugs, cell-based and gene-therapy products), Category 2 (Active Pharmaceutical Ingredients, Key Starting Materials, and drug intermediates), and Category 3 (in-vitro diagnostic devices and other drugs not manufactured in India) with differential eligibility and differential incentive rates. Claims are filed quarterly through the DoP PLI portal against the FY 2019-20 base year (pre-scheme baseline), and incremental sales are computed as Year N sales minus FY 2019-20 base — a reconstruction most manufacturers did not intend at the time. The Section 115BAA versus Section 35(2AB) election trade-off adds another layer: the 115BAA concessional 22 percent rate forfeits the 35(2AB) DSIR-recognised R&D weighted deduction, and the PLI recipient must model the multi-year cash-tax versus book-tax curve before either election is locked.
How TransactIG solves this
TransactIG is built by Terra Insight with pharmaceuticals-specific configuration, not generic matching logic.
Per-plant per-month Rule 89(5) refund workbook with Chapter-27 carve-out
TransactIG runs the Rule 89(5) Net-ITC calculation per plant per month under the Notification 14/2022 amended formula, segregates every input invoice by HSN code and by finished-goods HSN linkage, and — critically — excludes Chapter 27 solvent input tax and other Notification 09/2022-blocked inputs from the refund pool so the RFD-01 draft that goes to the department carries only recoverable heads. Rule 42/43 apportionment for the nil-rated life-saving portion is applied per common input, with the monthly Table 4(B) reversal and the annual Table 5H reconciliation produced without a separate spreadsheet cycle.
PLI Pharma DoP-portal quarterly claim reconciliation with base-year bridge
The PLI module reconstructs the FY 2019-20 base-year sales per Category 1/2/3 SKU, tracks Year N quarterly sales against the base, computes incremental sales per the DoP notification, and produces the quarterly claim workbook that lines up with the DoP PLI portal fields. The Section 115BAA versus 35(2AB) election trade-off is modelled per FY so finance can compare the cash-tax impact of the concessional-rate election against the R&D-deduction forfeit before the election is locked for the year.
USFDA Form 483 remediation cost accounting with Section 37 / Ind AS 16 split
USFDA Form 483 observations and Warning Letters trigger remediation spend across facility upgrades, equipment replacement, external consultants, retraining, revalidation batches, and CAPA-linked scrap. TransactIG tags every remediation invoice by observation reference, classifies it as revenue expense under Section 37 of the Income Tax Act versus capital expense under Ind AS 16 (asset improvement or new capitalisable component), links Ind AS 37 provision entries for pending observations that have not yet crystallised in vendor invoices, and produces the audit-grade trail that both statutory auditors and tax officers ask for during scrutiny.
Reconciliation patterns
Configuration presets
No custom development
These presets are included with every Pharmaceuticals deployment of TransactIG. Go live in 2–4 weeks.
Regulatory framework
Pharmaceuticals reconciliation in India operates within the following regulatory bodies and compliance frameworks.
Frequently asked questions
How does TransactIG handle Rule 89(5) inverted-duty refund now that Notification 14/2022 amended the formula and the 22-September-2025 GST 2.0 pivot deepened the inversion?
TransactIG runs the Rule 89(5) Net-ITC calculation per plant per month using the Notification 14/2022 amended formula, which specifies that Net ITC excludes ITC on input services and capital goods and that the refund is capped at the tax payable on inverted-rated supplies. For the 22-September-2025 GST 2.0 rate cut — all drugs at 5 percent, medical devices at 5 percent, notified life-saving formulations at nil — Chapter 30 output sits below Chapter 39/48 packaging (18 percent), Chapter 27 solvent (18 percent), and utility inputs, so the deeper inversion is quantified and pushed into the monthly RFD-01 draft against the Council FAQ Q10 / Q25 / Q51 expedited-refund pledge. Rule 42/43 apportionment for the nil-rated life-saving portion is applied per common input, and the annual Table 5H reconciliation in GSTR-9 is generated automatically.
Notification 09/2022 permanently blocks Chapter 27 solvent ITC from Rule 89(5) refund. How does TransactIG stop that blocked ITC from leaking into the RFD-01 claim?
Notification 09/2022-Central Tax (Rate) dated 13-July-2022, effective from 18-July-2022, added Chapter 27 goods (mineral fuels, mineral oils, and their distillation products) to the permanent-block list for Rule 89(5). TransactIG tags every input invoice against the HSN code of the finished good it feeds; ITC linked to Chapter 27 solvent (hexane, IPA, methanol, toluene, ethyl acetate) is segregated at ingestion and excluded from the Rule 89(5) Net-ITC pool so it never surfaces on the RFD-01 draft. The blocked ITC remains in the books as a permanent cost on the API line, and the segregation is retained through to the departmental audit trail. ITC on non-Chapter-27 heads (packaging, API precursors, utilities where not blocked, capital goods per formula) is claimed normally.
How does TransactIG handle the loan-licensing job-work chain — Section 143 CGST 1-year clock, Rule 45 challans, ITC-04 quarterly filing, and MSME Section 43B(h) 45-day discipline?
Every despatch of APIs, intermediates, or packaging under a job-work agreement is issued on a Rule 45 challan with the challan ID carried through the system. TransactIG runs the Section 143 1-year clock (3 years for capital goods, moulds, dies, jigs, fixtures) per challan lot and escalates the exposure at 9 months and again at 11 months so a supplementary invoice, extension application, or recall can be filed before the deeming provision activates and triggers GST-plus-interest from the despatch date. The ITC-04 filing (quarterly for turnover above Rs 5 crore, half-yearly below) is produced challan-wise. For loan-licensor payments, the Udyam classification per vendor is maintained; the 45-day (written agreement) or 15-day (no agreement) MSMED clock runs from GRN date; and Section 43B(h) disallowance exposure is quantified with MSMED interest computed at 3x bank rate for delayed payments.
How is PLI Pharma incremental sales reconciled against the FY 2019-20 base year in the DoP PLI portal claim workflow, and how is the Section 115BAA vs 35(2AB) election modelled?
TransactIG reconstructs the FY 2019-20 base-year sales per Category 1 (biopharmaceuticals, complex generics, patented drugs, cell-based and gene-therapy products), Category 2 (APIs, KSMs, intermediates), and Category 3 (IVD and other drugs not manufactured in India) at the SKU level, tracks Year N quarterly sales against the base, computes incremental sales per the DoP notification, and produces the quarterly claim workbook that lines up with the DoP PLI portal input fields. For the Section 115BAA versus 35(2AB) election, the multi-year cash-tax curve under 115BAA (22 percent concessional rate, no 35(2AB) R&D weighted deduction) is modelled against the curve under the default regime plus 35(2AB) DSIR-recognised R&D deduction (with Form 3CLA approval and Form 3CL certification), so finance can lock the election on evidence rather than instinct.
USFDA Form 483 remediation spend needs Section 37 revenue-expense versus Ind AS 16 capex classification per invoice. How does TransactIG handle that?
Every Form 483 observation is tagged with an observation reference (typically observation number and inspection date). Remediation invoices — facility upgrades, HVAC re-qualification, equipment replacement, external consultants (regulatory, QMS), retraining programmes, revalidation batches, CAPA scrap — are linked to the observation, classified per invoice as Section 37 revenue expense (repairs, ongoing compliance, consulting on operational fixes) versus Ind AS 16 capex (new capitalisable component, asset improvement extending life or capacity), and posted with the classification carried into the tax computation and the financial statements. Pending observations that have not yet crystallised in vendor invoices are covered by Ind AS 37 provision entries, and Warning-Letter-linked spend is escalated so the CFO sees the full exposure before the year-end close.
Ready to automate Pharmaceuticals reconciliation?
Terra Insight will walk you through a live TransactIG demo using pharmaceuticals transaction data — matching patterns, variance taxonomy, and ERP integration.